Friedreich’s Ataxia Market

Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be of several types such as spinocerebellar ataxia, Friedreich’s ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and others. Friedreich’s ataxia can develop at any age and is progressive in nature i.e. it worsens with time. Friedreich’s ataxia (FA) is a genetic ataxia that is caused when a damaged gene which leads to FA is passed from one generation to the other. In addition to common movement related symptoms, people suffering from Friedreich’s ataxia also experience symptoms such as stiffness and loss of sensation in muscles, weakness in the body, heart condition (hypertrophic cardiomyopathy), and others.

Market Dynamics

High burden of Friedreich’s ataxia, rising technological advancements, and increasing adoption of inorganic growth strategies such as acquisitions, mergers, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global Friedreich’s ataxia  market over the forecast period.

For instance, according to a review article published by the Frontiers in Neuroscience journal, a peer-reviewed open access scientific journal, in February 2022, it was estimated that the prevalence of Friedreich ataxia was 1:50,000 individuals, around the globe as of 2021

Moreover, in February 2019, the University of Oxford, England and Harrington Discovery Institute at University Hospitals in Ohio, U.S. announced a global partnership to address unmet need of patients suffering from rare diseases such as muscular dystrophy, cystic fibrosis, ataxia, and others

Key features of the study:

• This report provides an in-depth analysis of the global Friedreich’s ataxia  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new Material launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Friedreich’s ataxia  market based on the following parameters – company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics, Design Therapeutics, Inc., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
• The global Friedreich’s ataxia  market report caters to various stakeholders in this industry including investors, suppliers, Material manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Friedreich’s ataxia market

Detailed Segmentation:

• Global Friedreich’s Ataxia Market, By Drug Class:
  • ACE Inhibitors
  • Beta Blockers
  • Diuretics
  • Para-Benzoquinone
  • Others (Vitamin E, immunomodulators, skeletal muscle relaxants, and anti-epileptic drugs, among others)
• Global Friedreich’s Ataxia Market, By Route of Administration:
  • Oral
  • Injectable
• Global Friedreich’s Ataxia Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Friedreich’s Ataxia Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Reata Pharmaceuticals, Inc.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Retrotope Inc.
  • Minoryx
  • PTC Therapeutics
  • Design Therapeutics, Inc.
  • Larimar Therapeutics, Inc.
  • Jupiter Neurosciences, Inc.
  • Lexeo Therapeutics
  • Zydus Lifesciences Ltd.
  • Cipla Limited
  • GlaxoSmithKline Plc.
  • Aurobindo Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.